CD22 CHO Recombinant Cell Line (Medium Expression)

Catalog #: 79557-M
Size: 2 vials
CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body’s B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.

Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771). Surface expression of CD22 was confirmed by flow cytometry. This clonal cell line was selected for medium level expression of CD22. A clone exhibiting higher levels of CD22 expression is also available (#79557-H). Please contact BPS Bioscience for additional information.

Supplied As:
Each vial contains ~ 2.5 x 106 cells in 1 ml of Thaw Media + 10% DMSO.
Host Cell line:
CHO K1 cell line, Chinese Hamster Ovary
Mycoplasma Testing:
This cell line has been screened using the Quick Test Mycoplasma Detection Kit (, #B39032) to confirm the absence of Mycoplasma contamination.
Growth Media:

Thaw Medium 3 (BPS Bioscience, #60186): Ham’s F-12 medium (Hyclone #SH30526.01) supplemented with 10% FBS (Life Technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 3D (BPS Bioscience, #79539):  Thaw Medium 3 (BPS Bioscience, #60186) plus 1 mg/ml G418 (Thermo Fisher, #11811031).

Storage / Stability:
Store in liquid nitrogen immediately upon receipt.
Useful for screening and validating antibodies against CD22 and different CD22 CAR-T for immunotherapy research and drug discovery. Also useful for CD22 binding assays to screen for CD22 ligands.

1. Poe J, et al. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012 Aug; 33(8):413-420.

2. Dorner T, et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews. 2015 14:1079-1086.

3. Wei G., et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. Journal of Hematology and Oncology. 2017 10:1-13.


License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

Avoid freeze/thaw cycles
Scientific Category:
Product Type:
Cell line
Data shown is lot-specific. Contact us for specific information on other lots.

Quality Assurance

Product Datasheets